Opdivo Approval Expanded to Include Lung Cancer

March 4, 2015 7:20 PM

6 0

WEDNESDAY, March 4, 2015 (HealthDay News) -- U.S. Food and Drug Administration approval of Opdivo (nivolumab) has been expanded to include advanced non-small cell lung cancer (NSCLC), the agency said Wednesday in a news release.

Lung cancer is the leading cause of cancer death in the United States, having been diagnosed more than 224,000 times and causing more than 159,000 deaths in 2014, the FDA said. NSCLC is the most common type, affecting seven of eight people with lung cancer.

Read more

To category page